Despite advances in managing systemic lupus erythematosus (SLE) and lupus nephritis (LN), disease burden remains high, with many patients who remain undertreated or refractory to treatment, leading to increased risk for significant morbidity, accrual of progressive organ damage, reduced quality of life, and increased mortality. Current treatments often have substantial side effects, highlighting the need for safer and more effective options. The heterogeneity of SLE also complicates treatment, as responses vary widely among individuals. Emerging therapies have shown efficacy in clinical trials and may help to change the disease course, potentially transforming the management of this challenging condition. Join this live symposium for an interactive, case-based discussion in which experts will review the latest recommendations for the management of SLE and LN and engage in a quickfire question-based review of emerging therapies that hold promise for improving patient outcomes.